Cardiovascular disease (CVD) -including heart disease and stroke- is the primary cause of death in the US. It is a multifactorial disease in which the number of risk factors correlates with disease progression and worse outcome. While age remains the greatest risk factor for stroke, other conditions, such as hypertension, diabetes, and sickle cell disease (SCD), render both adults and children vulnerable to ischemic stroke, e.g. 24% of SCD patients have a stroke by the age of 45 and 11% by the age of 20. It is therefore not surprising that SCD is frequently referred to as a 'hypercoagulable state', and whilst it is already known that neutrophils of SCD patients are activated, and that they play a role in peripheral thrombosis, their role in cerebral thrombosis has not been characterized. Therefore, the innovative proposed research outlined in this project will lead to further understanding the prothrombogenic phenotype of SCD, and uncover the potential implication of targeting neutrophils as a therapeutic strategy and treatment for this debilitating and life threatening disease.
|Program type||Innovative Research Grant|
|Effective start/end date||01/01/2016 → 12/31/2017|